Myriad Genetics Launches New Four-in-One Prenatal Genetic Screen
Myriad Genetics has officially launched FirstGene, a new prenatal screening test. This development changes how doctors approach early pregnancy diagnostics by consolidating four distinct tests into a single blood draw. The test is available as early as eight weeks into pregnancy, providing results in approximately 10 days.
FirstGene combines fetal chromosome screening, single-gene screening, patient carrier status, and fetal RhD screening into one report. By gathering this data from a single sample, the test removes the need for additional samples from a reproductive partner. This approach targets efficiency in clinical workflows and allows for earlier discussions between obstetricians and their patients.
The test covers critical health markers including trisomy 21, 18, and 13, as well as sex chromosome aneuploidies and 22q11.2 microdeletion. Beyond fetal markers, it evaluates the patient for 20 recessive conditions such as cystic fibrosis, spinal muscular atrophy, sickle cell disease, and fragile X syndrome. The company reports an analytical sensitivity greater than 98% and a specificity greater than 99%.
Brian Donnelly, chief commercial officer at Myriad Genetics, stated that the test uses a new method to gain clinical insights from maternal blood. Dr. Dallas Reed, principal medical advisor at the company, noted that this change assists clinicians in providing complete information during the early stages of pregnancy. This launch expands the existing portfolio of genetic testing options offered by the company for prenatal care.
By moving these multiple modalities into one order, the company aims to simplify the logistical burden for medical offices. This launch represents a shift toward more integrated diagnostic tools in maternal health, focusing on accuracy and speed. Clinicians can now manage a broader range of screening requirements through a single point of interaction with the patient, potentially leading to faster medical decisions.